Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective.

Journal of molecular modeling - 7 Aug 2026

Li Minyu, Jiang Xu, Du Tingting, Xu Shenqian, Liu Wuxia, Qiu Xiaoou, Liang Wenqi, Zheng Guodong, Zhang Jingfeng, Wang Wei

Abstract excerpt

CONTEXT: The tropomyosin receptor kinase (TRK) family regulates key oncogenic signaling pathways, and genetic alterations in NTRK genes are implicated in a broad spectrum of malignancies. Although TRK inhibitors such as entrectinib effectively demonstrate robust clinical efficacy in NTRK fusion-positive tumors, their long-term therapeutic utility is frequently limited by the emergence of acquired resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydrogen Bonding

Share to Indazoles

Share to Molecular Dynamics Simulation

Share to Receptor, trkA

Share to Thermodynamics

Share to Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 42566048
DOI: 10.1007/s00894-026-06880-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mechanistic basis of G595R-mediated resistance to entrectinib in TRK kinase: a structural-energetic perspective.PMID 42566048Read ↗

Lessons from Structural Biology for Understanding Drug Resistance in Gastrointestinal Stromal Tumors (GIST).Semantic proximity Read ↗

Discovery of Next-Generation Tropomyosin Receptor Kinase Inhibitors for Combating Multiple Resistance Associated with Protein Mutation.Semantic proximity Read ↗

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.Semantic proximity Read ↗

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.Semantic proximity Read ↗

In silico evaluation of the resistance of the T790M variant of epidermal growth factor receptor kinase to cancer drug Erlotinib.Semantic proximity Read ↗

Discovery of Next-Generation Tropomyosin Receptor Kinase (TRK) Inhibitors for Combatting Resistance Associated with Protein MutationSemantic proximity Read ↗

Microsecond Molecular Dynamics Simulation to Gain Insight Into the Binding of MRTX1133 and Trametinib With KRASG12D Mutant Protein for Drug Repurposing.Semantic proximity Read ↗

Elucidating the role of the T790M mutation in BLU-945 selectivity for mutant EGFR: structural and energetic insights.Semantic proximity Read ↗

Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.Semantic proximity Read ↗

Unveiling KRAS G12D inhibition: from molecular dynamics to therapeutic strategies.Semantic proximity Read ↗

Integrating computational chemistry and machine learning to predict KRAS mutation-induced resistanceSemantic proximity Read ↗

Dissecting the role of ALK double mutations in drug resistance to lorlatinib with in-depth theoretical modeling and analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.